Latest news with #StimulatorofInterferonGenes
Cision Canada
2 days ago
- Business
- Cision Canada
Curadev Expands Strategic Collaboration for CRD3874-SI Through MSK Therapeutics Accelerator Program
BOSTON, June 10, 2025 /CNW/ -- Curadev Pharma, Inc., a clinical-stage biotechnology company developing novel immuno-oncology therapeutics, and Memorial Sloan Kettering Cancer Center (MSK), a world-leading cancer research and treatment institution, are expanding their collaboration through the MSK Therapeutics Accelerator program to advance the development of Curadev's small-molecule allosteric Stimulator of Interferon Genes (STING) agonist, CRD3874-SI, to be delivered systemically to patients with advanced/metastatic cancer. The collaboration builds on the ongoing Phase 1a/b dose escalation and expansion clinical trial (NCT06021626) currently underway at MSK for sarcoma and Merkel cell carcinoma patients, and aims to explore the potential of CRD3874-SI in treating additional types of cancer. Through the MSK Therapeutics Accelerator program, MSK will provide Curadev with expertise and institutional resources, including medical, clinical, and regulatory advice, to further the development of CRD3874-SI. This expanded collaboration marks a significant milestone in translating promising STING pathway research into broader clinical application and will be overseen by William Tap, MD, Chief of the Sarcoma Medical Oncology Service at MSK, and Ciara Kelly, MBBCh BAO, Interim Clinical Director of MSK's Sarcoma Oncology Service. Dr. William Tap said, "MSK and its Division of Solid Tumors are excited to co-develop CRD3874-SI, a novel first-in-class allosteric STING agonist, with Curadev. CRD3874-SI has demonstrated an encouraging safety and efficacy profile in a first-in-human study at MSK. CRD3874-SI is moving forward into multiple solid-tumor expansion cohorts, guided by disease specific experts and the support and structure of the MSK Accelerator Program, which is designed to enhance and expedite the development of novel compounds across malignancies. CRD3874-SI has the potential to offer patients a new treatment option with continued innovation and exploration of the benefits of immunotherapy in cancer care." Dr. Arjun Surya, Co-founder and CEO of Curadev, added, "We are encouraged by the early readouts with CRD3874-SI systemic monotherapy from our ongoing clinical trial in patients with treatment refractory cancers at MSK and are honored by the opportunity to deepen our collaboration through the MSK Therapeutics Accelerator program. The research and development collaboration between oncologists at MSK and the inventors of CRD3874-SI at Curadev could become a role model for advancing bench to bedside medicines. MSK's historic leadership position in the development of cancer immunotherapy and the exemplary dedication of the oncologists we work with is inspiring and make it an ideal partner in Curadev's effort to investigate the therapeutic potential of its systemically administered allosteric STING agonist in patients with advanced/metastatic cancer." About Curadev Curadev is a clinical-stage biotechnology company dedicated to discovering and developing novel small-molecule therapeutics for treating intractable diseases. Curadev has built an impressive portfolio of discovery research programs using a target-centric approach, innovative screening schemes, and traditional wet-lab chemistry and pharmacology, resulting in patent-protected drug candidates that modulate next-generation drug targets. Curadev Pharma, Inc., the US-based clinical development subsidiary founded in 2021, is currently leading the Phase1/2 trials of STING agonist assets under a US FDA-approved IND application. For more information, visit MSK's Therapeutics Accelerator program is a strategic partnership program between MSK and biotechnology companies to advance novel cancer therapeutics through all stages of drug development. The program brings together innovative healthcare companies with MSK's community of clinical and scientific experts to establish groundbreaking collaborations that can have a tangible impact on the treatment or management of cancer.
Jordan News
25-03-2025
- Health
- Jordan News
Revolutionary Discovery Opens the Door to New Treatments for COVID-19 and Alzheimer's - Jordan News
Scientists have made a groundbreaking discovery in understanding autoimmune diseases, potentially opening the door to new treatments for conditions like COVID-19 and Alzheimer's disease. اضافة اعلان Researchers from the University of Washington and the University of Pennsylvania have made a scientific breakthrough that could change the future of medicine by unveiling the protein ArfGAP2, which plays a crucial role in regulating immune responses. This important discovery came by chance while studying a rare disease known as vascular inflammation associated with the Stimulator of Interferon Genes (STING) protein, which affects one child in every million and causes the immune system to attack healthy tissues, especially in the lungs and extremities. This disease is often fatal before reaching adulthood, resulting from excessive activity of the STING protein, which is supposed to help the body detect viral DNA and trigger immune responses. However, in cases of vascular inflammation associated with STING, this protein remains constantly active, leading to chronic immune responses and tissue damage. The scientists found that this protein acts as a critical link between immune system activation and the release of inflammatory substances. Through a series of precise experiments, the research team demonstrated that disabling this protein in mice with vascular inflammation associated with STING completely halted tissue damage, potentially paving the way for developing new treatments for autoimmune diseases. What's even more exciting is that these results could extend to common diseases like COVID-19 and Alzheimer's, where inflammation plays a key role in their development. To explain how it works, the researchers used a powerful analogy, describing the discovered protein as the "traffic controller at a train station," which regulates the release of "trains" (inflammatory substances) from immune cells. Without this controller, the harmful inflammatory process halts while preserving beneficial immune functions. This new understanding represents a significant shift in immunology, as it provides the long-missing link in understanding how the immune system shifts from being a protector to attacking the body itself. Currently, the team is working on developing drug molecules that specifically target this protein, with clinical trials expected to begin within the next three years. If successful, these efforts could spark a real revolution in the treatment of a wide range of diseases affecting millions worldwide, from rheumatoid arthritis to multiple sclerosis, and potentially even some neurodegenerative diseases.
